Deep brain stimulation for hyperkinetic disorders.
Deep brain stimulation (DBS) has a record of safety and efficacy for an expanding range of indications. Recently,the Food and Drug Administration provided approval through a Humanitarian Device Exemption for DBS of the globus pallidus internus and subthalamic nucleus for the treatment of dystonia. There is increasing clinical experience demonstrating that DBS is also effective for other hyperkinetic disorders such as chorea from a variety of causes. The selection criteria, intraoperative targeting, and the postoperative management of DBS for hyperkinetic disorders are discussed.
Montgomery
Erwin B
EB
Department of Neurology, National Primate Research Center, University of Wisconsin-Madison, Wisconsin 53792, USA. montgomery@neurology.wisc.edu
D000328:Adult; D002648:Child; D020821:Dystonic Disorders / Q000503:physiopathology / Q000628:therapy*; D004599:Electric Stimulation Therapy / Q000009:adverse effects / Q000941:ethics / Q000295:instrumentation / Q000379:methods; D004567:Electrodes, Implanted; D005917:Globus Pallidus / Q000503:physiopathology; D006801:Humans; D006948:Hyperkinesis / Q000503:physiopathology / Q000628:therapy*; D018579:Patient Selection; D020531:Subthalamic Nucleus / Q000503:physiopathology; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration